Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Navidea Biopharma (NAVB) Reports Q2 Loss of $0.24
August 8, 2019 5:35 PM EDTNavidea Biopharma (NYSE: NAVB) reported Q2 EPS of ($0.24), versus ($0.29) reported last year. Revenue for the quarter came in at $260.09 million, versus $542.13 million reported last year.
Second Quarter 2019 Highlights and Subsequent Events
Effected a one-for-twenty reverse stock split and received notification of stock price compliance from the NYSE AmericanAnnounced that results of the Companys NAV3-21 clinical study for diagnosis of rheumatoid arthritis were presented at the... More